Nuvation Bio Inc. Marketable Securities, Unrealized Gain (Loss)
Nuvation Bio Inc. (NUVB) reported Marketable Securities, Unrealized Gain (Loss) of $1.67 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Other Income
us-gaap:MarketableSecuritiesUnrealizedGainLoss · last filed 2026-08-06
- Nuvation Bio Inc. marketable securities, unrealized gain (loss) for the quarter ending 2026-06-30 was $454.00K, a 100.88% increase year-over-year.
- Nuvation Bio Inc. marketable securities, unrealized gain (loss) for the quarter ending 2026-03-31 was $1.21M, a 147.76% increase year-over-year.
- Nuvation Bio Inc. marketable securities, unrealized gain (loss) for the quarter ending 2025-12-31 was $531.00K, a 67.20% decline year-over-year.
- Nuvation Bio Inc. marketable securities, unrealized gain (loss) for the quarter ending 2025-09-30 was -$501.00K.
- Nuvation Bio Inc. marketable securities, unrealized gain (loss) for fiscal 2025 was $746.00K.
- Nuvation Bio Inc. marketable securities, unrealized gain (loss) for fiscal 2024 was -$157.00K, a 102.82% decline from fiscal 2023.
- Nuvation Bio Inc. marketable securities, unrealized gain (loss) for fiscal 2023 was $5.57M.
- Nuvation Bio Inc. marketable securities, unrealized gain (loss) for fiscal 2022 was -$5.57M.
| Period end | Marketable Securities, Unrealized Gain (Loss) 3 month | Marketable Securities, Unrealized Gain (Loss) 3 month as first filed | Marketable Securities, Unrealized Gain (Loss) 6 month | Marketable Securities, Unrealized Gain (Loss) 6 month as first filed | Marketable Securities, Unrealized Gain (Loss) 9 month | Marketable Securities, Unrealized Gain (Loss) 9 month as first filed | Marketable Securities, Unrealized Gain (Loss) 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $454.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $1.67M 10-Q · filed 2026-08-06 | $2.20M derived: sum of 3 quarters · filed 2026-08-06 | $1.70M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2026-03-31 | $1.21M 10-Q · filed 2026-05-04 | $1.75M derived: sum of 2 quarters · filed 2026-05-04 | $1.24M derived: sum of 3 quarters · filed 2026-05-04 | $1.47M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-12-31 | $531.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $30.00K derived: sum of 2 quarters · filed 2026-03-02 | $256.00K derived: sum of 3 quarters · filed 2026-08-06 | $746.00K 10-K · filed 2026-03-02 | |||
| 2025-09-30 | -$501.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | -$275.00K derived: sum of 2 quarters · filed 2026-08-06 | $215.00K 10-Q · filed 2025-11-03 | $1.83M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-06-30 | $226.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $716.00K 10-Q · filed 2026-08-06 | $2.33M derived: sum of 3 quarters · filed 2026-08-06 | -$1.04M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-03-31 | $490.00K 10-Q · filed 2026-05-04 | $2.11M derived: sum of 2 quarters · filed 2026-05-04 | -$1.27M derived: sum of 3 quarters · filed 2026-05-04 | -$1.02M derived: sum of 4 quarters · filed 2026-05-04 | |||
| 2024-12-31 | $1.62M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$1.76M derived: sum of 2 quarters · filed 2026-03-02 | -$1.51M derived: sum of 3 quarters · filed 2026-03-02 | -$157.00K 10-K · filed 2026-03-02 | |||
| 2024-09-30 | -$3.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | -$3.13M derived: sum of 2 quarters · filed 2025-11-03 | -$1.78M 10-Q · filed 2025-11-03 | $1.78M 10-Q · filed 2024-11-06 | $1.75M derived: sum of 4 quarters · filed 2025-11-03 | ||
| 2024-06-30 | $252.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $1.60M 10-Q · filed 2025-08-07 | -$1.60M 10-Q · filed 2024-08-05 | $5.12M derived: sum of 3 quarters · filed 2025-08-07 | $6.23M derived: sum of 4 quarters · filed 2025-08-07 | ||
| 2024-03-31 | $1.35M 10-Q · filed 2025-05-07 | -$1.35M 10-Q · filed 2024-05-14 | $4.87M derived: sum of 2 quarters · filed 2025-05-07 | $5.98M derived: sum of 3 quarters · filed 2025-05-07 | $4.42M derived: sum of 4 quarters · filed 2025-05-07 | ||
| 2023-12-31 | $3.52M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $4.63M derived: sum of 2 quarters · filed 2025-03-06 | $3.08M derived: sum of 3 quarters · filed 2025-03-06 | $5.57M 10-K · filed 2025-03-06 | |||
| 2023-09-30 | $1.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$447.00K derived: sum of 2 quarters · filed 2024-11-06 | $2.04M 10-Q · filed 2024-11-06 | $4.34M derived: sum of 4 quarters · filed 2024-11-06 | |||
| 2023-06-30 | -$1.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05 | $936.00K 10-Q · filed 2024-08-05 | $3.23M derived: sum of 3 quarters · filed 2024-08-05 | $1.90M derived: sum of 4 quarters · filed 2024-08-05 | |||
| 2023-03-31 | $2.49M 10-Q · filed 2024-05-14 | $4.78M derived: sum of 2 quarters · filed 2024-05-14 | $3.45M derived: sum of 3 quarters · filed 2024-05-14 | $2.00M derived: sum of 4 quarters · filed 2024-05-14 | |||
| 2022-12-31 | $2.29M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $960.00K derived: sum of 2 quarters · filed 2024-02-29 | -$494.00K derived: sum of 3 quarters · filed 2024-02-29 | -$5.57M 10-K · filed 2024-02-29 | |||
| 2022-09-30 | -$1.33M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | -$2.79M derived: sum of 2 quarters · filed 2023-11-02 | -$7.86M 10-Q · filed 2023-11-02 | -$9.40M derived: sum of 4 quarters · filed 2023-11-02 | |||
| 2022-06-30 | -$1.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$6.53M 10-Q · filed 2023-08-03 | -$8.07M derived: sum of 3 quarters · filed 2023-08-03 | -$8.43M derived: sum of 4 quarters · filed 2023-08-03 | |||
| 2022-03-31 | -$5.08M 10-Q · filed 2023-05-04 | -$6.62M derived: sum of 2 quarters · filed 2023-05-04 | -$6.98M derived: sum of 3 quarters · filed 2023-05-04 | -$8.26M derived: sum of 4 quarters · filed 2023-05-04 | |||
| 2021-12-31 | -$1.54M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | -$1.90M derived: sum of 2 quarters · filed 2023-03-15 | -$3.19M derived: sum of 3 quarters · filed 2023-03-15 | -$2.66M 10-K · filed 2023-03-15 | |||
| 2021-09-30 | -$359.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$1.64M derived: sum of 2 quarters · filed 2022-11-03 | -$1.11M 10-Q · filed 2022-11-03 | -$1.25M derived: sum of 4 quarters · filed 2022-11-03 | |||
| 2021-06-30 | -$1.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$754.00K 10-Q · filed 2022-08-04 | -$886.00K derived: sum of 3 quarters · filed 2022-08-04 | -$1.12M derived: sum of 4 quarters · filed 2022-08-04 | |||
| 2021-03-31 | $531.00K 10-Q · filed 2022-05-09 | -$531.00K 10-Q · filed 2021-05-17 | $399.00K derived: sum of 2 quarters · filed 2022-05-09 | $168.00K derived: sum of 3 quarters · filed 2022-05-09 | $1.05M derived: sum of 4 quarters · filed 2022-05-09 | ||
| 2020-12-31 | -$132.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | -$363.00K derived: sum of 2 quarters · filed 2022-02-28 | $520.00K derived: sum of 3 quarters · filed 2022-02-28 | $1.35M 10-K · filed 2022-02-28 | |||
| 2020-09-30 | -$231.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $652.00K derived: sum of 2 quarters · filed 2021-11-10 | $1.49M 10-Q · filed 2021-11-10 | ||||
| 2020-06-30 | $883.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $1.72M 10-Q · filed 2021-08-12 | |||||
| 2020-03-31 | $834.00K 10-Q · filed 2021-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |